LH01 - Myoviridae
Introduction to the Myoviridae Family and LH01
LH01-Myoviridae belongs to the Myoviridae family of bacteriophages, characterized by their complex morphology, which includes an icosahedral head (capsid) containing double-stranded DNA (dsDNA) and a distinct, contractile tail. Bacteriophages are the most abundant biological entities on Earth, serving as natural regulators of bacterial populations. In the context of human health and sports nutrition, LH01 is utilized as a highly specific, non-fermentative 'prebiotic'—often termed a phage prebiotic. Unlike traditional prebiotics (such as fructooligosaccharides or inulin) that serve as fermentable substrates for beneficial bacteria, LH01 operates through competitive exclusion. By selectively lysing specific strains of *Escherichia coli*, LH01 frees up spatial niches and nutritional resources in the gastrointestinal (GI) tract, thereby indirectly promoting the proliferation of beneficial genera such as *Bifidobacterium* and *Lactobacillus*.
Viral Attachment and Receptor Specificity
The initial and most critical step in the mechanism of LH01-Myoviridae is its highly specific attachment to the target bacterial cell. This specificity is mediated by the phage's tail fibers, which recognize and bind to specific receptors on the outer membrane of the target *E. coli* strains. These receptors are typically lipopolysaccharides (LPS) or specific outer membrane proteins (OMPs). The binding is a two-step process: an initial, reversible attachment mediated by long tail fibers, followed by an irreversible binding involving short tail fibers extending from the phage baseplate. This lock-and-key mechanism ensures that LH01 only targets specific, often undesirable, bacterial strains, leaving the vast majority of the commensal microbiome—including beneficial probiotics—completely unharmed. This extreme specificity is a significant advantage over broad-spectrum antibiotics or even broad-acting antimicrobial botanicals.
DNA Injection and Host Hijacking
Upon irreversible binding to the bacterial surface, the contractile tail of the Myoviridae phage undergoes a dramatic conformational change. The tail sheath contracts, driving a rigid central tail tube through the bacterial outer membrane and peptidoglycan layer. The phage then injects its dsDNA from the capsid, through the tail tube, and into the bacterial cytoplasm. Once inside, the phage DNA immediately begins to hijack the host cell's molecular machinery. The host's RNA polymerase is co-opted to transcribe 'early' phage genes, which encode proteins that halt host DNA, RNA, and protein synthesis. The bacterial cell is effectively transformed into a factory dedicated solely to the production of new bacteriophages. 'Middle' and 'late' gene expression follows, leading to the replication of the phage genome and the synthesis of structural proteins (capsid heads, tail sheaths, baseplates, and tail fibers).
The Lytic Cycle and Amplification
LH01 is an obligate lytic phage, meaning it does not integrate its DNA into the host genome (lysogeny) but instead proceeds directly to the lytic cycle. As the newly synthesized phage components self-assemble into mature virions within the bacterial cytoplasm, the phage expresses two critical proteins: holin and endolysin. Holins form pores in the inner bacterial membrane, allowing the endolysins to access and degrade the peptidoglycan cell wall. This degradation weakens the cell wall to the point where it can no longer withstand the internal osmotic pressure of the bacterium. The cell undergoes sudden lysis (bursting), releasing dozens to hundreds of newly formed LH01 phages into the surrounding GI environment. This 'burst size' allows for exponential amplification of the phage population at the site of the target bacteria, ensuring a rapid and robust response to the presence of the target *E. coli* strains.
Microbiome Modulation and Prebiotic-Like Effects
The lysis of target *E. coli* by LH01 has profound downstream effects on the gut microbiome. First, the physical removal of these competitive bacteria opens up binding sites on the intestinal epithelium, allowing beneficial probiotic strains to adhere and colonize more effectively. Second, the lysis of the bacterial cells releases their intracellular contents—including amino acids, nucleotides, and complex carbohydrates—into the local microenvironment. This phenomenon, known as 'cross-feeding,' provides a highly bioavailable nutrient source for neighboring beneficial bacteria. Clinical studies have demonstrated that the administration of LH01 (typically as part of a 4-phage blend) leads to significant increases in the populations of *Bifidobacterium bifidum*, *Lactobacillus acidophilus*, and other health-promoting taxa. Because this prebiotic effect is achieved without the fermentation of exogenous fibers, it completely bypasses the production of gases (hydrogen, methane, carbon dioxide) that cause the bloating and flatulence commonly associated with traditional prebiotics.
Pharmacokinetics and Gastrointestinal Survivability
From a pharmacokinetic perspective, bacteriophages are unique because they are self-replicating biological entities rather than static chemical compounds. When ingested orally, LH01 must survive the harsh, acidic environment of the stomach and the bile salts of the upper intestine. Research indicates that LH01, particularly when formulated correctly or consumed with food/water, exhibits robust survivability through the upper GI tract, reaching the colon in viable, infective states. Unlike traditional drugs, phages exhibit 'auto-dosing' pharmacokinetics: their concentration increases exponentially in the presence of their target host and declines rapidly once the host population is depleted. Phages are generally not absorbed systemically in significant quantities; they remain localized in the GI lumen where they exert their effects. Any phages that do translocate across the intestinal epithelium are rapidly cleared by the reticuloendothelial system (primarily the liver and spleen) without causing an immune or inflammatory response, underscoring their high safety profile.
What is LH01-Myoviridae? +
Is LH01-Myoviridae a virus? Will it make me sick? +
How is LH01 different from a probiotic? +
Does LH01-Myoviridae cause gas and bloating? +
What is PreforPro? +
What is the clinical dose of LH01? +
How long does it take for LH01 to work? +
Should I take LH01 with food or on an empty stomach? +
Can I take LH01 with antibiotics? +
Does LH01 kill good bacteria? +
Is LH01 safe for daily use? +
Why is it called a 'phage prebiotic'? +
Can LH01 help with IBS? +
Does LH01 need to be refrigerated? +
Can I stack LH01 with other supplements? +
Everything About LH01 - Myoviridae Article
Introduction: The Phage Revolution in Gut Health
For decades, the standard approach to improving gut health has been a two-pronged strategy: introduce beneficial bacteria (probiotics) and feed them with fermentable fibers (prebiotics). While effective in theory, this approach has a significant flaw. Traditional prebiotics, such as inulin, fructooligosaccharides (FOS), and galactooligosaccharides (GOS), require massive doses (often 5 to 10 grams) and rely on bacterial fermentation. This fermentation process produces gases—hydrogen, methane, and carbon dioxide—leading to severe bloating, cramping, and flatulence in many users.
Enter bacteriophages. Bacteriophages, or simply 'phages,' are microscopic viruses that exclusively target and destroy bacteria. They are the most abundant biological entities on the planet, acting as nature's population control for bacteria. In the realm of sports nutrition and clinical gastroenterology, specific phages like LH01-Myoviridae are revolutionizing how we approach microbiome modulation. By acting as a 'phage prebiotic,' LH01 offers a highly targeted, non-fermentative way to boost beneficial gut bacteria without any of the gas or bloating associated with traditional fibers.
What is LH01-Myoviridae?
LH01-Myoviridae is a specific strain of bacteriophage belonging to the Myoviridae family. Under an electron microscope, these phages look like microscopic lunar landers. They possess an icosahedral head (which houses their double-stranded DNA) and a complex, contractile tail mechanism used to inject that DNA into target bacteria.
In dietary supplements, LH01 is almost exclusively found as a component of PreforPro®, a patented four-phage blend developed by Deerland Probiotics & Enzymes (now part of ADM). The blend typically includes LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae. Together, these phages are engineered to target specific, often problematic strains of Escherichia coli in the human gut.
The Problem with Traditional Prebiotics
To understand the value of LH01, we must understand the limitations of traditional prebiotics:
1. The Fermentation Problem: Fibers like inulin feed beneficial bacteria, but the byproduct of this feeding frenzy is gas. For athletes or individuals with sensitive GI tracts (like those with IBS), this gas causes painful bloating that can interfere with training and daily life. 2. The Dosage Problem: To be effective, traditional prebiotics require large doses. You cannot fit 5 grams of inulin into a standard dietary supplement capsule; it requires large scoops of powder. 3. The Specificity Problem: Fermentable fibers are broad-spectrum. While they feed good bacteria, they can also inadvertently feed opportunistic or pathogenic bacteria if the gut is already dysbiotic.
How LH01-Myoviridae Works: A Microscopic Hitman
LH01-Myoviridae solves all three of these problems through a completely different biochemical mechanism. It does not feed bacteria; it destroys the competition.
1. Targeted Attachment LH01 is incredibly specific. Its tail fibers act like a key that only fits a specific lock—in this case, receptors on the outer membrane of target E. coli strains. It ignores beneficial bacteria like Lactobacillus and Bifidobacterium entirely.
2. Hijacking and Replication Once attached, LH01 injects its DNA into the E. coli. It hijacks the bacterium's cellular machinery, forcing it to stop its normal functions and instead produce dozens of new LH01 phages.
3. Lysis (Bursting) The newly formed phages produce enzymes (holins and endolysins) that break down the bacterial cell wall from the inside out. The E. coli cell bursts (lyses), releasing the new phages to hunt down more E. coli.
4. The Prebiotic Effect (Competitive Exclusion and Cross-Feeding) This is where the 'prebiotic' magic happens. By destroying the E. coli, LH01 clears out physical space on the intestinal wall. Furthermore, when the E. coli bursts, it releases its internal nutrients (amino acids, sugars, nucleotides) into the gut environment. Beneficial bacteria like Bifidobacterium swoop in, consume these highly bioavailable nutrients, and rapidly multiply. This is achieved with zero fermentation and zero gas production.
Clinical Evidence and Efficacy
The clinical data supporting LH01 (via the PreforPro blend) is robust and growing. A landmark randomized, double-blind, placebo-controlled trial known as the PHAGE study (Febvre et al., 2019) investigated the effects of a 15mg daily dose of the phage blend in healthy adults.
The results were striking. Within days, participants taking the phage blend showed a significant reduction in target E. coli populations. Concurrently, researchers observed an increase in beneficial taxa, including Bifidobacterium bifidum and Lactobacillus acidophilus. Crucially, the study confirmed that the bacteriophage supplementation was exceptionally well-tolerated, with participants reporting no increase in gastrointestinal distress, bloating, or changes in bowel movement frequency compared to the placebo group.
Another study by Grubb et al. (2020) corroborated these findings, demonstrating that the phage blend not only modulated the microbiota but also increased the populations of bacteria known to produce short-chain fatty acids (SCFAs) like butyrate, which are essential for gut barrier integrity and reducing systemic inflammation.
Synergy with Probiotics
Because LH01-Myoviridae acts as a 'fertilizer' by clearing weeds (E. coli) to let the grass (probiotics) grow, it is highly synergistic when stacked with traditional probiotic supplements.
When you consume a standard probiotic capsule, those billions of CFUs (colony-forming units) enter a highly competitive environment. The native gut flora is already established, and space is limited. By co-administering LH01, you actively clear out competitive space just as the new probiotics arrive, drastically increasing their chances of successful colonization. This is why many premium gut health supplements now feature a combination of spore-forming probiotics (like Bacillus subtilis) alongside the PreforPro phage blend.
Safety, Tolerability, and Side Effects
The idea of ingesting a 'virus' can be alarming to some, but it is vital to understand that bacteriophages are entirely harmless to human cells. They lack the biological mechanisms to attach to, enter, or infect eukaryotic (human) cells. You already have billions of naturally occurring bacteriophages in your gut right now; LH01 is simply a concentrated dose of a specific, helpful strain.
Clinical trials have consistently shown that LH01 is safe and well-tolerated. It does not cause the 'die-off' symptoms (Herxheimer reaction) sometimes associated with broad-spectrum antibiotics, nor does it cause the severe flatulence associated with fiber prebiotics.
Dosing Protocols and Best Practices
One of the greatest advantages of LH01-Myoviridae is its micro-dosing capability. Because phages self-replicate once they find their target host, you do not need a massive dose to see an effect.
The clinically validated dose for the total phage blend (PreforPro) is just 15mg per day. This tiny dose easily fits into a single capsule alongside other ingredients.
Best Practices for Supplementation: Timing: Can be taken at any time of day, though taking it alongside a meal may help buffer stomach acid and improve the survivability of the phages as they travel to the intestines. Stacking: Highly recommended to stack with a high-quality, multi-strain probiotic to maximize the synergistic effects. Consistency: While phages begin working within hours, the downstream effects of microbiome modulation (improved digestion, reduced inflammation) typically take 1 to 2 weeks of consistent daily use to become noticeable.
The Future of Bacteriophage Therapy in Sports Nutrition
As our understanding of the gut-muscle axis and the gut-brain axis deepens, the importance of a healthy microbiome for athletic performance, recovery, and cognitive focus cannot be overstated. Systemic inflammation originating from gut dysbiosis can impair recovery, reduce nutrient absorption, and negatively impact mood and energy levels.
LH01-Myoviridae represents the cutting edge of targeted microbiome modulation. By offering a precise, bloat-free method to optimize gut flora, phage prebiotics are poised to replace traditional, bulky fiber prebiotics in premium sports nutrition and wellness formulations. Whether you are an elite athlete looking to maximize nutrient partitioning or an everyday individual seeking relief from digestive discomfort, LH01 offers a scientifically validated, elegant solution.